363 related articles for article (PubMed ID: 35793078)
1. Statin Eligibility for Primary Prevention of Cardiovascular Disease According to 2021 European Prevention Guidelines Compared With Other International Guidelines.
Mortensen MB; Tybjærg-Hansen A; Nordestgaard BG
JAMA Cardiol; 2022 Aug; 7(8):836-843. PubMed ID: 35793078
[TBL] [Abstract][Full Text] [Related]
2. ACC/AHA guidelines superior to ESC/EAS guidelines for primary prevention with statins in non-diabetic Europeans: the Copenhagen General Population Study.
Mortensen MB; Nordestgaard BG; Afzal S; Falk E
Eur Heart J; 2017 Feb; 38(8):586-594. PubMed ID: 28363217
[TBL] [Abstract][Full Text] [Related]
3. Statin Use in Primary Prevention of Atherosclerotic Cardiovascular Disease According to 5 Major Guidelines for Sensitivity, Specificity, and Number Needed to Treat.
Mortensen MB; Nordestgaard BG
JAMA Cardiol; 2019 Nov; 4(11):1131-1138. PubMed ID: 31577339
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the European and US guidelines for lipid-lowering therapy in primary prevention of cardiovascular disease.
Delabays B; de La Harpe R; Vollenweider P; Fournier S; Müller O; Strambo D; Graham I; Visseren FLJ; Nanchen D; Marques-Vidal P; Vaucher J
Eur J Prev Cardiol; 2023 Nov; 30(17):1856-1864. PubMed ID: 37290056
[TBL] [Abstract][Full Text] [Related]
5. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines for cardiovascular disease prevention in a European cohort.
Kavousi M; Leening MJ; Nanchen D; Greenland P; Graham IM; Steyerberg EW; Ikram MA; Stricker BH; Hofman A; Franco OH
JAMA; 2014 Apr; 311(14):1416-23. PubMed ID: 24681960
[TBL] [Abstract][Full Text] [Related]
6. Comparison of ACC/AHA and ESC Guideline Recommendations Following Trial Evidence for Statin Use in Primary Prevention of Cardiovascular Disease: Results From the Population-Based Rotterdam Study.
Pavlovic J; Greenland P; Deckers JW; Brugts JJ; Kavousi M; Dhana K; Ikram MA; Hofman A; Stricker BH; Franco OH; Leening MJ
JAMA Cardiol; 2016 Sep; 1(6):708-13. PubMed ID: 27439175
[TBL] [Abstract][Full Text] [Related]
7. Guidelines versus trial-evidence for statin use in primary prevention: The Copenhagen General Population Study.
Mortensen MB; Nordestgaard BG
Atherosclerosis; 2022 Jan; 341():20-26. PubMed ID: 34959205
[TBL] [Abstract][Full Text] [Related]
8. Real-life evaluation of European and American high-risk strategies for primary prevention of cardiovascular disease in patients with first myocardial infarction.
Mortensen MB; Falk E
BMJ Open; 2014 Oct; 4(10):e005991. PubMed ID: 25326211
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Five Major Guidelines for Statin Use in Primary Prevention in a Contemporary General Population.
Mortensen MB; Nordestgaard BG
Ann Intern Med; 2018 Jan; 168(2):85-92. PubMed ID: 29297004
[TBL] [Abstract][Full Text] [Related]
10. CAC Score Improves Coronary and CV Risk Assessment Above Statin Indication by ESC and AHA/ACC Primary Prevention Guidelines.
Mahabadi AA; Möhlenkamp S; Lehmann N; Kälsch H; Dykun I; Pundt N; Moebus S; Jöckel KH; Erbel R;
JACC Cardiovasc Imaging; 2017 Feb; 10(2):143-153. PubMed ID: 27665163
[TBL] [Abstract][Full Text] [Related]
11. 2019 vs. 2016 ESC/EAS statin guidelines for primary prevention of atherosclerotic cardiovascular disease.
Mortensen MB; Nordestgaard BG
Eur Heart J; 2020 Aug; 41(31):3005-3015. PubMed ID: 32227172
[TBL] [Abstract][Full Text] [Related]
12. Utility of Nontraditional Risk Markers in Individuals Ineligible for Statin Therapy According to the 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines.
Yeboah J; Polonsky TS; Young R; McClelland RL; Delaney JC; Dawood F; Blaha MJ; Miedema MD; Sibley CT; Carr JJ; Burke GL; Goff DC; Psaty BM; Greenland P; Herrington DM
Circulation; 2015 Sep; 132(10):916-22. PubMed ID: 26224808
[TBL] [Abstract][Full Text] [Related]
13. Antihyperlipidemic Medication Treatment Patterns and Statin Adherence Among Patients with ASCVD in a Managed Care Plan After Release of the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol.
Bellows BK; Olsen CJ; Voelker J; Wander C
J Manag Care Spec Pharm; 2016 Aug; 22(8):892-900. PubMed ID: 27459651
[TBL] [Abstract][Full Text] [Related]
14. Guideline-based statin/lipid-lowering therapy eligibility for primary prevention and accuracy of coronary artery calcium and clinical cardiovascular events: The Multi-Ethnic Study of Atherosclerosis (MESA).
Flueckiger P; Qureshi W; Michos ED; Blaha M; Burke G; Sandfort V; Herrington D; Yeboah J
Clin Cardiol; 2017 Mar; 40(3):163-169. PubMed ID: 27859433
[TBL] [Abstract][Full Text] [Related]
15. Adoption of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline in Cardiology Practices Nationwide.
Pokharel Y; Tang F; Jones PG; Nambi V; Bittner VA; Hira RS; Nasir K; Chan PS; Maddox TM; Oetgen WJ; Heidenreich PA; Borden WB; Spertus JA; Petersen LA; Ballantyne CM; Virani SS
JAMA Cardiol; 2017 Apr; 2(4):361-369. PubMed ID: 28249067
[TBL] [Abstract][Full Text] [Related]
16. Eligibility for PCSK9 inhibitors based on the 2019 ESC/EAS and 2018 ACC/AHA guidelines.
Koskinas KC; Gencer B; Nanchen D; Branca M; Carballo D; Klingenberg R; Blum MR; Carballo S; Muller O; Matter CM; Lüscher TF; Rodondi N; Heg D; Wilhelm M; Räber L; Mach F; Windecker S
Eur J Prev Cardiol; 2021 Mar; 28(1):59-65. PubMed ID: 33755142
[TBL] [Abstract][Full Text] [Related]
17. Primary Prevention With Statins: ACC/AHA Risk-Based Approach Versus Trial-Based Approaches to Guide Statin Therapy.
Mortensen MB; Afzal S; Nordestgaard BG; Falk E
J Am Coll Cardiol; 2015 Dec; 66(24):2699-2709. PubMed ID: 26700832
[TBL] [Abstract][Full Text] [Related]
18. Retrospective examination of lipid-lowering treatment patterns in a real-world high-risk cohort in the UK in 2014: comparison with the National Institute for Health and Care Excellence (NICE) 2014 lipid modification guidelines.
Steen DL; Khan I; Ansell D; Sanchez RJ; Ray KK
BMJ Open; 2017 Feb; 7(2):e013255. PubMed ID: 28213597
[TBL] [Abstract][Full Text] [Related]
19. Comparing eligibility for statin therapy for primary prevention under 2022 USPSTF recommendations and the 2018 AHA/ACC/ multi-society guideline recommendations: From National Health and Nutrition Examination Survey.
Gupta K; Kakar TS; Jain V; Gupta M; Al Rifai M; Slipczuk L; Nambi V; Bittner V; Blumenthal RS; Stone NJ; Lavie CJ; Virani SS
Prog Cardiovasc Dis; 2022; 75():78-82. PubMed ID: 36038004
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease.
Pandya A; Sy S; Cho S; Weinstein MC; Gaziano TA
JAMA; 2015 Jul; 314(2):142-50. PubMed ID: 26172894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
